Data reporting tools
Joint Application Package System
The World Health Organization (WHO) recommends using a range of broad-spectrum anthelminthic drugs in public health efforts to control and eliminate major helminth infections through an integrated approach to preventive chemotherapy (PC).
This method targets multiple helminth diseases simultaneously, where feasible and epidemiologically justified. WHO supports the integrated PC implementation by ensuring the availability of essential medicines like diethylcarbamazine citrate (DEC), albendazole, mebendazole, praziquantel, and ivermectin for combating diseases such as lymphatic filariasis, schistosomiasis, soil-transmitted helminths, and onchocerciasis. To aid in the efficient distribution and reporting of these medicines, WHO has introduced a joint mechanism comprising the Joint Request for Selected PC Medicines (JRSM), the Joint Reporting Form (JRF), and the PC Epidemiological Data Reporting Form (EPIRF), streamlining the process for countries to request medicines, report annual progress, and submit epidemiological data.
Countries must submit their medicine requests and progress reports through the JAP, including signed and scanned copies of JRSM and JRF, along with the full Excel files of JRSM, JRF, and EPIRF. Key guidelines include updating the JRF after each mass drug administration (MDA) round and submitting it by 31 March of the following year, requesting medicines at least 9 months before the planned MDA date, and annually submitting the EPIRF. The approval of JRSM is contingent upon the final JRF submission, with any deviations from the plan requiring detailed explanations in the JRF.
